JURA Bio, Inc.

The Convergence Forum Fellows Program supports talent development through the participation and engagement of promising under-represented researchers and founders from life sciences companies or working on research in the life sciences underwritten by industry partners. We are proud to present the 2024 Class of Fellows and look forward to meeting them at this year's conference: Rachel Salzman, DVM, Alvaro Amorrortu, Roya Khosravi-Far, Ph.D., PLD, Robert Shaffer, PhD, Andrew Thomson, Nele Van Dessel, Phuong Jean Pham, Shana W., Ananya Zutshi, Julia Pian, MD, Minmin Yen, Ph.D., MPH (she/her), Cheri Ackerman, Afreen Allam, Natalie J. Galant, PhD, Kwamane D. Liddell, JD, MHA, BSN, Elizabeth Wood. To learn more about the Convergence Forum, visit https://lnkd.in/ejeUvSBb

I still can't believe that I'll get to go on the same stage as Yael Weiss, Charlene Son Rigby, John F. Crowley, Sarah Boyce, Paul Hastings, and Belinda Termeer herself to share my and JURA Bio, Inc.'s small part of the story of combining the best people, the best technologies, and the best communities to advance therapies for rare and other diseases. If you're planning on being in #SanDiego for #BIO2024, I hope that you'll help support The Termeer Foundation by joining us at the Connections Empowering Cures 2024 event. Registration info for the event is here: https://lnkd.in/ePuYKYt4. Hope to see you there!

MassBio's 2024 State of Possible Conference & Align Summit: A Showcase of Innovation and Leadership Last week marked a significant milestone for the Termeer Foundation as our fellows showcased their groundbreaking work at MassBio’s 2024 State of Possible Conference and Align Summit. These events, pivotal in advancing Massachusetts’ role as a global leader in life sciences, provided our fellows an excellent platform to present their innovative solutions and gain invaluable insights from industry leaders. Fellows Making Strides During the two conferences, the foundation's commitment to nurturing biotech leaders was prominently on display. Natalie J. Galant, PhD (2023 Termeer Fellow), CEO and cofounder at Paradox Immunotherapeutics, and Shardule Shah, PhD, MBA (2024 Termeer Fellow), CEO of Lime Therapeutics, took the stage on the second day to pitch their cutting-edge research, demonstrating the potential of their projects to address critical medical needs. Stan Wang, MD, PhD (2020 Termeer Fellow and CEO of Thymmune Therapeutics) contributed significantly as a panelist, sharing his expertise and insights into the evolving biotech landscape. Their presentations and discussions underscored the foundation’s role in empowering the next generation of biotech innovators. Honoring Excellence in Leadership A highlight of the conference was the recognition of Dr. Susan Windham-Bannister, CEO of Biomedical Growth Strategies, who was honored with the Henri A. Termeer Innovative Leadership Award. Dr. Windham-Bannister, known for her transformative impact on the Massachusetts life sciences sector, exemplifies the leadership qualities that the Termeer Foundation strives to cultivate in its programs. Her work has not only advanced the industry but also set a benchmark for leadership and commitment to community. Recognition from Industry Leaders The conference also featured a special mention by Kendalle Burlin O'Connell, Esq., CEO of MassBio, who applauded Elizabeth Wood, CEO of JURA Bio, Inc. and 2022 Termeer Fellow, for her exceptional contributions to biotech. This acknowledgment from a leading industry figure highlights the foundation’s success in supporting individuals who are pushing the boundaries of biotechnology. As the biotech landscape continues to evolve, the Termeer Foundation remains dedicated to supporting Termeer fellows through mentorship, recognition, and access to key industry events. We are proud to see our fellows shine at such high-profile venues and are excited about the future contributions they will make to healthcare and patient lives. #stateofpossible24 #alignsummit24 #womeninbiotech #latinosinbio #leadership #STEM #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #PatientCare #GlobalCollaboration #Massachusetts #biotechnology #lifescience #bio #health #pharma #peopleempoweringcures #connectionsempoweringcures #leadershipmatters #healthcare #mentorship #science #mentor #leader #ceo #lifescience #bio #TermeerFellows

🧱 Builders w/ Lachlan MacKinnon & Adrian Woolfson @ Replay 🚀 Embark on an exhilarating journey into the future of healthcare with Replay Bio! Led by visionary founders Lachlan McKinnon & Adrian Wolfson, Replay Bio pioneers genomic medicine with cutting-edge technology. Explore their revolutionary hub-and-spoke model, seamlessly integrating design, synthesis, & delivery platforms. Dive into their core product companies: Cyana, Eudora, Teleria, & Genera, driving breakthroughs in TCRNK cell therapy & HSV gene therapy. Plus, discover their recent partnership with JURA Bio, Inc. to develop TCRs for Sienna, enhancing the efficacy of cell therapies. Join us as we delve deeper into the genomic revolution, shaping the landscape of medicine for generations to come! Tune in: https://buff.ly/4bqcXLR #GenomicRevolution #BiotechInnovators #HealthcareTransformation

JURA Bio, Inc. is proud to announce that we'll be presenting our work on armored eMHC-CAR-T and eMHC-CAR-NK for the depletion of antigen-specific T cells associated with autoimmune diseases and oncologic T cell malignancies at the 27th Annual Meeting of the American Society of Gene & Cell Therapy in Baltimore, Maryland, May 6-10. Head of Research Cameron Gardner, PhD, will be in attendance. Abstracts now available online: https://lnkd.in/eKiSKA4 Meet us there or online at www.jurabio.com. #ASGCT #CellTherapy #AutoimmuneDisease

Catch JURA Bio CEO/Co-founder Elizabeth Wood speaking at tomorrow's exciting BIOTECH XYZ event, featuring a fantastic blend of biotech entrepreneurs, academics, and investors. We hope you tune in at 6:00PM ET!

Join our CEO Elizabeth Wood at BIOTECH XYZ February 21st in NYC for a great panel on AI + drug development -- all the way from discovery through regulatory and commercial challenges and opportunities.

So excited for JURA Bio, Inc. Director of Research Cameron Gardner to present tomorrow at Phacilitate #AdvancedTherapiesWeek #ATW24. If you’re in Miami and interested in TCR development (or even protein design more broadly), make sure you check out the session.

It is almost wheels-up for JURA Bio, Inc., destination: #JPM2024! Following an exciting 2023, we are #SanFrancisco-bound to join friends and colleagues at the J.P. Morgan 42nd Annual Healthcare Conference. JURA Bio, Inc.’s #BiotechShowcase2024 participation: JURA Bio, Inc. CEO Elizabeth Wood will share our journey on the frontier of curative therapies on Tuesday,  January 9, at 8:00AM PST in Yosemite A at the Hilton San Francisco Union Square. Learn more about how JURA is harnessing a combination of synthetic biology and probabilistic machine learning to help us design, build and test the next generation of genomic medicine at extraordinary scale in this BTS workshop panel. Members of our team in attendance: Elizabeth Wood, Co-Founder and CEO Julie Norville, Co-Founder and CTO Follow JURA Bio, Inc. and stay on top of our latest happenings. TO SCHEDULE A MEETING WITH US: team@jurabio.com MEDIA CONTACT: team@jurabio.com #PersonalizedMedicine #Therapeutics #Biotech #Biotechnology #Biopharma #Healthcare #Partnering #Innovation #Therapeutics #JURABioInc

Great Interview with George Church on the impact of AI on molecular biology, particularly in protein engineering. Few appreciate how how early and influential the lab has been in shaping the current revolution in AI protein design — both in developing new computational techniques and experimental methods: from the first 'protein language models' [1] and AI-driven protein engineering methods [2] to learning 'virtual fitness landscapes' of protein function [3] using massively multiplexed in vivo barcodes [4]. While purely computational models like AlphaFold and ESM get a lot of attention, it's becoming clear that the integration of wet and dry lab is the key to achieving real-world success with generative AI in bio and (hopefully) designing next generation of breakthrough medicines. I expect a disproportionate number of those to come from Church Lab spinouts like Nabla Bio, Inc., Dyno Therapeutics, Manifold Bio, 64x Bio, Patch Biosciences, JURA Bio, Inc. and others who share their hybrid ethos and are building 'damp labs' of their own like Inceptive, Profluent Bio, NOETIK and CHARM Therapeutics. H/T to Surge Biswas, Grigory Khimulya, Ethan Alley, Mohammed AlQuraishi, Gleb Kuznetsov, Pierce Ogden, Eric Kelsic, Sam Sinai, Kevin Esvelt, Nazim Bouatta, Ratul Chowdhury, cc Jakob Uszkoreit, Do Soon Kim, Ali Madani, Ron Alfa, MD, PhD, Jacob Rinaldi, Lacey Padrón, Laksh Aithani, Lexi Rovner, Eeshit Dhaval Vaishnav, Carl de Boer, Arjun Manrai, Seth Bannon, Jeff Huber, Uri Laserson, JB Michel, Frances Anastassacos, Julie Norville